交易 ORIC Pharmaceuticals, Inc. - ORIC CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
| 价差 | 0.05 | ||||||||
|
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
|
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
| 隔夜费时间 | 21:00 (UTC) | ||||||||
| 最小交易量 | 1 | ||||||||
| 货币 | USD | ||||||||
| 保证金 | 20% | ||||||||
| 上市交易所 | United States of America | ||||||||
| 交易费 | 0% |
*Information provided by Capital.com
Oric Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
|---|---|---|---|---|---|---|
| Jun 7, 2023 | 5.67 | 0.39 | 7.39% | 5.28 | 5.89 | 5.28 |
| Jun 6, 2023 | 5.47 | 0.16 | 3.01% | 5.31 | 5.61 | 5.23 |
| Jun 5, 2023 | 5.28 | 0.05 | 0.96% | 5.23 | 5.31 | 5.06 |
| Jun 2, 2023 | 5.26 | -0.01 | -0.19% | 5.27 | 5.40 | 5.26 |
| Jun 1, 2023 | 5.25 | 0.27 | 5.42% | 4.98 | 5.36 | 4.89 |
| May 31, 2023 | 4.97 | 0.07 | 1.43% | 4.90 | 5.01 | 4.86 |
| May 30, 2023 | 5.01 | -0.03 | -0.60% | 5.04 | 5.08 | 4.94 |
| May 26, 2023 | 5.01 | 0.00 | 0.00% | 5.01 | 5.11 | 4.99 |
| May 25, 2023 | 5.13 | 0.04 | 0.79% | 5.09 | 5.16 | 4.97 |
| May 24, 2023 | 5.13 | -0.01 | -0.19% | 5.14 | 5.20 | 4.99 |
| May 23, 2023 | 5.16 | -0.03 | -0.58% | 5.19 | 5.41 | 5.13 |
| May 22, 2023 | 5.19 | 0.26 | 5.27% | 4.93 | 5.20 | 4.93 |
| May 19, 2023 | 4.94 | 0.02 | 0.41% | 4.92 | 5.04 | 4.89 |
| May 18, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.01 | 4.85 |
| May 17, 2023 | 4.96 | 0.02 | 0.40% | 4.94 | 5.05 | 4.83 |
| May 16, 2023 | 4.99 | -0.10 | -1.96% | 5.09 | 5.17 | 4.95 |
| May 15, 2023 | 5.10 | 0.00 | 0.00% | 5.10 | 5.21 | 5.01 |
| May 12, 2023 | 5.08 | -0.12 | -2.31% | 5.20 | 5.20 | 5.05 |
| May 11, 2023 | 5.15 | 0.07 | 1.38% | 5.08 | 5.25 | 4.99 |
| May 10, 2023 | 5.12 | 0.26 | 5.35% | 4.86 | 5.27 | 4.85 |
ORIC Pharmaceuticals, Inc. Events
| 时间（协调世界时） (UTC) | 国家/地区 | 事件 |
|---|---|---|
| Wednesday, June 14, 2023 | ||
| 时间（协调世界时） (UTC) 15:00 | 国家/地区 US
| 事件 Oric Pharmaceuticals Inc Annual Shareholders Meeting Oric Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 16, 2023 | ||
| 时间（协调世界时） (UTC) 15:00 | 国家/地区 US
| 事件 Oric Pharmaceuticals Inc Annual Shareholders Meeting Oric Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 9, 2023 | ||
| 时间（协调世界时） (UTC) 10:59 | 国家/地区 US
| 事件 Q2 2023 Oric Pharmaceuticals Inc Earnings Release Q2 2023 Oric Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| 时间（协调世界时） (UTC) 21:05 | 国家/地区 US
| 事件 Q3 2023 Oric Pharmaceuticals Inc Earnings Release Q3 2023 Oric Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 总收入 | 0 | 0 | 0 | 0 | 0 |
| 总营业费用 | 91.767 | 78.871 | 74.186 | 28.569 | 22.371 |
| 销售/一般/行政费用，总计 | 25.087 | 22.013 | 13.422 | 5.725 | 3.345 |
| 研究与开发 | 66.68 | 56.858 | 35.921 | 22.844 | 19.026 |
| 营业收入 | -91.767 | -78.871 | -74.186 | -28.569 | -22.371 |
| 利息收入（费用），非经营净值 | 2.645 | 0.141 | 0.306 | 1.397 | 0.775 |
| 其他，净值 | 0 | 0.015 | 0.177 | 0.289 | 0.233 |
| 税前净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 税后净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 未计算非常项目前的净收益 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 普通股股东可获收益 (不含非经常性项目) | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 普通股股东可获收益 (含非經常性項目) | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 摊薄净收入 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 摊薄后加权平均股 | 39.6553 | 37.9543 | 21.9425 | 27.5424 | 27.5424 |
| 扣除特别项目的每股摊薄盈利 | -2.24742 | -2.07394 | -3.35892 | -0.97606 | -0.77564 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| 每股正常摊薄盈利 | -2.24742 | -2.07394 | -2.22673 | -0.97606 | -0.77564 |
| 异常费用（收入） | 0 | 24.843 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| 总收入 | 0 | 0 | 0 | 0 | 0 |
| 总营业费用 | 25.678 | 22.119 | 25.694 | 20.696 | 23.258 |
| 销售/一般/行政费用，总计 | 6.162 | 5.824 | 5.971 | 6.862 | 6.43 |
| 研究与开发 | 19.516 | 16.295 | 19.723 | 13.834 | 16.828 |
| 营业收入 | -25.678 | -22.119 | -25.694 | -20.696 | -23.258 |
| 利息收入（费用），非经营净值 | 1.733 | 1.272 | 0.865 | 0.409 | 0.099 |
| 其他，净值 | 0 | ||||
| 税前净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 税后净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 未计算非常项目前的净收益 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 普通股股东可获收益 (不含非经常性项目) | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 普通股股东可获收益 (含非經常性項目) | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 摊薄净收入 | -23.945 | -20.847 | -24.829 | -20.287 | -23.159 |
| 摊薄后加权平均股 | 45.0902 | 40.1305 | 39.5757 | 39.4816 | 39.4317 |
| 扣除特别项目的每股摊薄盈利 | -0.53105 | -0.51948 | -0.62738 | -0.51383 | -0.58732 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| 每股正常摊薄盈利 | -0.53105 | -0.51948 | -0.62738 | -0.51383 | -0.58732 |
| 异常费用（收入） |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 流动资产总额 | 210.457 | 240.522 | 296.697 | 89.999 | 43.724 |
| 现金和短期投资 | 206.272 | 236.979 | 293.6 | 89.159 | 42.636 |
| 现金等价物 | 66.84 | 226.006 | 78.446 | 89.159 | 42.636 |
| Prepaid Expenses | 4.185 | 3.543 | 3.097 | 0.84 | 1.088 |
| Total Assets | 247.178 | 298.642 | 298.997 | 94.093 | 46.734 |
| Property/Plant/Equipment, Total - Net | 3.253 | 2.413 | 1.981 | 2.241 | 2.514 |
| Property/Plant/Equipment, Total - Gross | 9.046 | 7.402 | 6.466 | 5.756 | 5.092 |
| Accumulated Depreciation, Total | -5.793 | -4.989 | -4.485 | -3.515 | -2.578 |
| Other Long Term Assets, Total | 11.517 | 12.321 | 0.319 | 1.853 | 0.496 |
| Total Current Liabilities | 15.388 | 15.151 | 9.002 | 5.354 | 2.596 |
| Accounts Payable | 1.32 | 1.886 | 0.757 | 0.152 | 0.446 |
| Accrued Expenses | 14.068 | 13.265 | 7.699 | 4.668 | 1.597 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.546 | 0.534 | 0.553 | |
| Total Liabilities | 24.827 | 25.666 | 9.221 | 6.119 | 3.894 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 9.439 | 10.515 | 0.219 | 0.765 | 1.298 |
| Total Equity | 222.351 | 272.976 | 289.776 | 87.974 | 42.84 |
| Preferred Stock - Non Redeemable, Net | 178.058 | 107.266 | |||
| Common Stock | 0.005 | 0.004 | 0.004 | 0.001 | 0.001 |
| Additional Paid-In Capital | 557.867 | 518.183 | 456.196 | 2.605 | 1.38 |
| Retained Earnings (Accumulated Deficit) | -335.521 | -245.211 | -166.424 | -92.69 | -65.807 |
| Total Liabilities & Shareholders’ Equity | 247.178 | 298.642 | 298.997 | 94.093 | 46.734 |
| Total Common Shares Outstanding | 45.0895 | 39.4301 | 36.6724 | 27.5424 | 27.5424 |
| 短期投资 | 139.432 | 10.973 | 215.154 | ||
| Long Term Investments | 21.951 | 43.386 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| 流动资产总额 | 193.164 | 210.457 | 198.685 | 233.526 | 239.085 |
| 现金和短期投资 | 189.629 | 206.272 | 193.659 | 227.064 | 234.622 |
| 现金等价物 | 58.99 | 66.84 | 29.076 | 49.08 | 112.644 |
| 短期投资 | 130.639 | 139.432 | 164.583 | 177.984 | 121.978 |
| Prepaid Expenses | 3.535 | 4.185 | 5.026 | 6.462 | 4.463 |
| Total Assets | 226.648 | 247.178 | 237.997 | 259.684 | 275.062 |
| Property/Plant/Equipment, Total - Net | 3.112 | 3.253 | 3.049 | 3.005 | 2.463 |
| Property/Plant/Equipment, Total - Gross | 9.158 | 9.046 | 8.684 | 8.456 | 7.692 |
| Accumulated Depreciation, Total | -6.046 | -5.793 | -5.635 | -5.451 | -5.229 |
| Other Long Term Assets, Total | 11.063 | 11.517 | 11.953 | 12.381 | 11.937 |
| Total Current Liabilities | 14.867 | 15.388 | 13.284 | 12.474 | 11.817 |
| Accounts Payable | 1.93 | 1.32 | 1.532 | 2.093 | 0.888 |
| Accrued Expenses | 12.937 | 14.068 | 11.752 | 10.381 | 10.929 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 23.836 | 24.827 | 23.178 | 22.814 | 21.983 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 8.969 | 9.439 | 9.894 | 10.34 | 10.166 |
| Total Equity | 202.812 | 222.351 | 214.819 | 236.87 | 253.079 |
| Common Stock | 0.005 | 0.005 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 561.481 | 557.867 | 529.945 | 526.651 | 522.144 |
| Retained Earnings (Accumulated Deficit) | -358.674 | -335.521 | -315.13 | -289.785 | -269.069 |
| Total Liabilities & Shareholders’ Equity | 226.648 | 247.178 | 237.997 | 259.684 | 275.062 |
| Total Common Shares Outstanding | 45.0912 | 45.0895 | 39.576 | 39.5755 | 39.4386 |
| Long Term Investments | 19.309 | 21.951 | 24.31 | 10.772 | 21.577 |
| Other Current Liabilities, Total | |||||
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 净收入/起跑线 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 |
| 经营活动产生的现金 | -75.143 | -59.541 | -45.268 | -23.533 | -20.683 |
| 经营活动产生的现金 | 0.966 | 0.897 | 0.97 | 1.028 | 0.903 |
| 非现金物品 | 13.458 | 14.204 | 25.42 | 1.102 | 0.484 |
| 营运资金的变化 | -0.445 | 4.073 | 2.045 | 1.22 | -0.707 |
| 投资活动产生的现金 | -109.248 | 158.435 | -215.959 | -0.768 | -0.508 |
| 资本支出 | -2.078 | -0.939 | -0.667 | -0.768 | -0.525 |
| 其他投资现金流量项目，总计 | -107.17 | 159.374 | -215.292 | 0 | 0.017 |
| 融资活动产生的现金 | 25.225 | 49.134 | 250.514 | 70.824 | 38.008 |
| 融资现金流项目 | -0.399 | -1.852 | -21.237 | -0.099 | 0 |
| 股票的发行（报废），净额 | 25.624 | 50.986 | 271.751 | 70.923 | 38.008 |
| 现金净变化 | -159.166 | 148.028 | -10.713 | 46.523 | 16.817 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -23.945 | -89.122 | -68.275 | -43.446 | -23.159 |
| Cash From Operating Activities | -20.628 | -75.143 | -59.814 | -40.494 | -22.718 |
| Cash From Operating Activities | 0.253 | 0.966 | 0.719 | 0.498 | 0.251 |
| Non-Cash Items | 2.753 | 13.458 | 10.908 | 7.985 | 3.987 |
| Changes in Working Capital | 0.311 | -0.445 | -3.166 | -5.531 | -3.797 |
| Cash From Investing Activities | 12.778 | -109.248 | -137.548 | -136.863 | -90.66 |
| Capital Expenditures | -0.31 | -2.078 | -1.791 | -1.39 | -0.723 |
| Other Investing Cash Flow Items, Total | 13.088 | -107.17 | -135.757 | -135.473 | -89.937 |
| Cash From Financing Activities | 0 | 25.225 | 0.432 | 0.431 | 0.016 |
| Issuance (Retirement) of Stock, Net | 0 | 25.624 | 0.432 | 0.431 | 0.016 |
| Net Change in Cash | -7.85 | -159.166 | -196.93 | -176.926 | -113.362 |
| Financing Cash Flow Items | -0.399 | 0 |
| 投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
|---|---|---|---|---|---|---|
| Pfizer Inc | Corporation | 11.9227 | 5376344 | 5376344 | 2022-12-23 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 8.8843 | 4006224 | -9509 | 2023-03-31 | LOW |
| The Column Group LP | Venture Capital | 7.9129 | 3568181 | 0 | 2023-03-31 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 7.58 | 3418068 | 0 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 5.0288 | 2267642 | -166208 | 2023-03-31 | HIGH |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 4.4668 | 2014241 | 0 | 2023-03-31 | LOW |
| Suvretta Capital Management, LLC | Hedge Fund | 4.2194 | 1902643 | 0 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.6437 | 1643074 | 96789 | 2023-03-31 | LOW |
| Prosight Capital | Hedge Fund | 3.4262 | 1545000 | 365000 | 2023-03-31 | HIGH |
| SilverArc Capital Management, LLC | Hedge Fund | 3.1844 | 1435945 | 199649 | 2023-03-31 | HIGH |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 3.0481 | 1374468 | -233100 | 2023-03-31 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 2.3374 | 1054000 | 0 | 2023-03-31 | LOW |
| Invus Financial Advisors, LLC | Hedge Fund | 2.2344 | 1007575 | 0 | 2023-03-31 | LOW |
| Chacko (Jacob M) | Individual Investor | 1.811 | 816652 | 3471 | 2023-03-31 | LOW |
| Euclidean Capital, L.L.C. | Investment Advisor | 1.6578 | 747550 | 0 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5144 | 682888 | -107508 | 2023-03-31 | LOW |
| Memorial Sloan-Kettering Cancer Center | Investment Advisor | 1.3356 | 602272 | 0 | 2023-03-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 1.2825 | 578303 | -24484 | 2023-03-31 | LOW |
| Monaco asset management S.A.M. | Investment Advisor | 1.2236 | 551749 | -5681 | 2023-03-31 | HIGH |
| Oppenheimer Asset Management Inc. | Investment Advisor | 0.8538 | 385011 | 0 | 2023-03-31 | LOW |
交易计算器
如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投资
交易规模（杠杆 x 投资）：
開倉
平仓
做空 做多
ORIC Pharmaceuticals, Inc. Company profile
关于 ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc.是一家临床阶段的生物制药公司，致力于通过克服癌症的抗药性来改善患者的生活。 公司专注于开发多样化的疗法，旨在利用其在三个特定领域的经验来对抗癌症的抗药性机制：激素依赖性癌症、精准肿瘤学和关键肿瘤依赖性。 其候选产品包括ORIC-101、ORIC-533、ORIC-944和ORIC-114。 公司的ORIC-101是一种强效和选择性的糖皮质激素受体（GR）的小分子拮抗剂，该受体与各种实体瘤对多类癌症治疗药物的抗性有关。 公司的第二个候选产品ORIC-533是一种可口服的CD73小分子抑制剂，CD73是化疗和免疫疗法治疗方案中腺苷途径的一个关键节点。 其ORIC-944正在开发用于治疗前列腺癌和乳腺癌。
| Industry: | Bio Therapeutic Drugs |
240 E. Grand Ave.
2Nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗？
加入成为全球535,000万多名交易者的一份子，选择利用Capital.com进行交易吧。